Selected research
Industry Research
Acute Agitation and Aggression Therapeutics Industry Research Report 2026
Market perspective
The global Acute Agitation and Aggression Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Acute Agitation and Aggression Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Acute Agitation and Aggression Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Acute Agitation and Aggression Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Acute Agitation and Aggression Therapeutics include Johnson & Johnson, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Otsuka Holdings, Ono Pharmaceutical, H. Lundbeck A/S and Bristol-Myers Squibb, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Acute Agitation and Aggression Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Acute Agitation and Aggression Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acute Agitation and Aggression Therapeutics Market by Company
Johnson & Johnson
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Otsuka Holdings
Ono Pharmaceutical
H. Lundbeck A/S
Bristol-Myers Squibb
Acute Agitation and Aggression Therapeutics Segment by Type
Oral
Intramuscular Injection
Others
Acute Agitation and Aggression Therapeutics Segment by Application
Oral
Intramuscular Injection
Others
Acute Agitation and Aggression Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Agitation and Aggression Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Agitation and Aggression Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Agitation and Aggression Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Acute Agitation and Aggression Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Intramuscular Injection
- Others
Applications
- Oral
- Intramuscular Injection
- Others
Companies covered
- Johnson & Johnson
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Otsuka Holdings
- Ono Pharmaceutical
- H. Lundbeck A/S
- Bristol-Myers Squibb
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Acute Agitation and Aggression Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 Intramuscular Injection
- 2.2.4 Others
- 2.3 Acute Agitation and Aggression Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oral
- 2.3.3 Intramuscular Injection
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Acute Agitation and Aggression Therapeutics Breakdown Data by Type
- 3.1 Global Acute Agitation and Aggression Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Acute Agitation and Aggression Therapeutics Forecasted Market Size by Type (2027-2032)
4 Acute Agitation and Aggression Therapeutics Breakdown Data by Application
- 4.1 Global Acute Agitation and Aggression Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Acute Agitation and Aggression Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Acute Agitation and Aggression Therapeutics Market Perspective (2021-2032)
- 5.2 Global Acute Agitation and Aggression Therapeutics Growth Trends by Region
- 5.2.1 Global Acute Agitation and Aggression Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Acute Agitation and Aggression Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Acute Agitation and Aggression Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Acute Agitation and Aggression Therapeutics Market Dynamics
- 5.3.1 Acute Agitation and Aggression Therapeutics Industry Trends
- 5.3.2 Acute Agitation and Aggression Therapeutics Market Drivers
- 5.3.3 Acute Agitation and Aggression Therapeutics Market Challenges
- 5.3.4 Acute Agitation and Aggression Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Acute Agitation and Aggression Therapeutics Players by Revenue
- 6.1.1 Global Top Acute Agitation and Aggression Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Acute Agitation and Aggression Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Acute Agitation and Aggression Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Acute Agitation and Aggression Therapeutics Head Office and Area Served
- 6.4 Global Acute Agitation and Aggression Therapeutics Players, Product Type & Application
- 6.5 Global Acute Agitation and Aggression Therapeutics Manufacturers Established Date
- 6.6 Global Acute Agitation and Aggression Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 7.2 North America Acute Agitation and Aggression Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 8.2 Europe Acute Agitation and Aggression Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 10.2 South America Acute Agitation and Aggression Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.1.4 Johnson & Johnson Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Eli Lilly and Company
- 12.2.1 Eli Lilly and Company Company Information
- 12.2.2 Eli Lilly and Company Business Overview
- 12.2.3 Eli Lilly and Company Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.2.4 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.2.5 Eli Lilly and Company Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.3.4 Pfizer Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GlaxoSmithKline
- 12.4.1 GlaxoSmithKline Company Information
- 12.4.2 GlaxoSmithKline Business Overview
- 12.4.3 GlaxoSmithKline Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.4.4 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.4.5 GlaxoSmithKline Recent Developments
- 12.5 Otsuka Holdings
- 12.5.1 Otsuka Holdings Company Information
- 12.5.2 Otsuka Holdings Business Overview
- 12.5.3 Otsuka Holdings Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.5.4 Otsuka Holdings Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.5.5 Otsuka Holdings Recent Developments
- 12.6 Ono Pharmaceutical
- 12.6.1 Ono Pharmaceutical Company Information
- 12.6.2 Ono Pharmaceutical Business Overview
- 12.6.3 Ono Pharmaceutical Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.6.4 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.6.5 Ono Pharmaceutical Recent Developments
- 12.7 H. Lundbeck A/S
- 12.7.1 H. Lundbeck A/S Company Information
- 12.7.2 H. Lundbeck A/S Business Overview
- 12.7.3 H. Lundbeck A/S Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.7.4 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.7.5 H. Lundbeck A/S Recent Developments
- 12.8 Bristol-Myers Squibb
- 12.8.1 Bristol-Myers Squibb Company Information
- 12.8.2 Bristol-Myers Squibb Business Overview
- 12.8.3 Bristol-Myers Squibb Revenue in Acute Agitation and Aggression Therapeutics Business (2021-2026)
- 12.8.4 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Product Portfolio
- 12.8.5 Bristol-Myers Squibb Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst